Biogen has already been granted FDA approval for a phase 4 post-marketing trial, and is running two other studies on the drug, one an extension of one of its earlier studies and the other an ...

Biogen has revealed encouraging phase 2 results ... of Nephrology (ASN), IgAN is an autoimmune kidney disease driven by immune cells that express a protein called CD38 on their surface.

with demonstrated proof of concept in multiple immune-mediated diseases, represents a key asset in Biogen’s late-stage immunology portfolio CAMBRIDGE, Mass., March 11, 2025 (GLOBE NEWSWIRE ...